--- title: "TuHURA Biosciences | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286617940.md" datetime: "2026-05-15T21:22:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286617940.md) - [en](https://longbridge.com/en/news/286617940.md) - [zh-HK](https://longbridge.com/zh-HK/news/286617940.md) --- # TuHURA Biosciences | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.13, missing the estimate of USD -0.115. EBIT: As of FY2026 Q1, the actual value is USD -7.523 M. #### Segment Revenue TuHURA Biosciences, Inc. operates in a single reportable segment and generated no segment revenue for the three months ended March 31, 2026, and 2025. #### Operational Metrics - **Net Loss**: The company reported a net loss of - $7,536,598 for the three months ended March 31, 2026, compared to - $6,664,371 for the same period in 2025. - **Operating Loss**: The operating loss was - $7,529,899 for the three months ended March 31, 2026, an increase from - $7,017,023 in the prior year period. - **Research and Development (R&D) Expenses**: R&D expenses increased by $0.7 million to $5,232,541 for the three months ended March 31, 2026, from $4,581,672 in 2025. This increase was driven by approximately $0.5 million in ongoing clinical development for TBS-2025 and approximately $1.0 million in facilities, salary, and personnel-related costs, offset by a decrease of approximately - $0.8 million in IFx-2.0 clinical development and approximately - $0.1 million in preclinical research. - **General and Administrative (G&A) Expenses**: G&A expenses rose by $0.3 million to $2,297,358 for the three months ended March 31, 2026, from $2,016,309 in 2025, primarily due to increased non-cash stock compensation and public company costs. - **Acquisition-related costs**: These costs were $0.0 million for the three months ended March 31, 2026, down from $0.4 million in 2025, reflecting costs incurred in relation to the Kineta Merger. - **Grant Income**: Grant income was $0.0 million for the three months ended March 31, 2026, compared to $0.3 million in 2025. - **Interest Expense**: Interest expense was - $27,974 for the three months ended March 31, 2026, with no comparable expense in 2025. - **Interest Income**: Interest income decreased to $21,275 for the three months ended March 31, 2026, from $100,098 in 2025. - **Stock-based Compensation Expense**: Total stock-based compensation expense was $2,796,240 for the three months ended March 31, 2026, up from $1,424,736 in 2025. - **Accumulated Deficit**: As of March 31, 2026, the accumulated deficit stood at - $148.7 million. #### Cash Flow - **Net Cash Used in Operating Activities**: TuHURA Biosciences, Inc. used - $4,412,953 in operating activities for the three months ended March 31, 2026, an improvement from - $4,738,422 in the same period of 2025. - **Net Cash Used in Investing Activities**: Net cash used in investing activities was - $48,846 for the three months ended March 31, 2026, significantly lower than - $1,151,047 in 2025. - **Net Cash Provided by Financing Activities**: Financing activities provided $7,139,977 in net cash for the three months ended March 31, 2026, a substantial increase from - $547,878 used in 2025. This was primarily driven by $7.0 million from common stock issuances and $0.5 million from Private Placement proceeds, partially offset by payments for deferred offering costs and principal payments on notes payable. - **Cash and Cash Equivalents**: As of March 31, 2026, cash and cash equivalents totaled $6.3 million. #### Unique Metrics - **Goodwill and In-Process Research and Development (IPR&D)**: As of March 31, 2026, goodwill was $10,738,082 and IPR&D was $11,275,000, both acquired in the Kineta Merger. #### Future Outlook and Strategy TuHURA Biosciences, Inc. anticipates continuing to incur significant operating losses as it advances product candidates through development and seeks regulatory approvals. The company’s existing capital resources, combined with a $50 million revolving credit facility and an At-The-Market (ATM) Program, are projected to be sufficient to fund operations until the end of 2028. Future funding requirements are dependent on clinical trial timelines, regulatory outcomes, and the ability to secure additional capital through equity, debt, or collaborations, with potential for dilution or relinquishing product rights if unfavorable terms are encountered. The company is advancing IFx-2.0 through a Phase 3 registration trial, planning a Phase 1b/2 trial for TBS-2025, and developing Delta Opioid Receptor (DOR) technology for bi-functional, bi-specific antibody-drug conjugates. ### Related Stocks - [HURA.US](https://longbridge.com/en/quote/HURA.US.md) ## Related News & Research - [TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update | HURA Stock News](https://longbridge.com/en/news/286615229.md) - [Torrid Reports First Quarter 2026 Results and Fiscal 2026 Guidance | CURV Stock News](https://longbridge.com/en/news/288766232.md) - [D2L GAAP EPS of $0.03, revenue of $57.13M](https://longbridge.com/en/news/289240195.md) - [Ferrellgas Partners, L.P. Reports Third Quarter Fiscal Year 2026 Results | FGPR Stock News](https://longbridge.com/en/news/288846789.md) - [Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Third Quarter of Fiscal 2026 Ended March 31, 2026 | GMHS Stock News](https://longbridge.com/en/news/289035965.md)